Pioneering Strategies for Technology Commercialization
ARCH Venture Partners invests in the development of seed and early stage
advanced technology companies that have the potential to grow rapidly into
successful businesses. We invest primarily in companies we co-found with leading
scientists and entrepreneurs, concentrating on bringing to market disruptive
innovations in life sciences, physical sciences and information technology, and
specialize in the spaces where they converge.
We enjoy special recognition as a leader in the successful commercialization of
technologies developed at academic research institutions, corporate research
groups and national laboratories.
Before the Buzzwords
Our team has deep scientific bench strength to locate and understand nascent
technologies long before they grow to become the popular industries of the day.
Our first nanotechnology investment was in 1989 (Nanophase Technologies) … our
first gene therapy and vaccine investments in 1992 (GenVec and Aviron) … our first
digital biology company was founded in 1993 (Illumina) … our first cleantech
company in 1994 (Eichrom Technologies) … and our first social networking investment
in 1996 (Classmates.com). The buzzwords hadn’t been formed yet, but the science, the
technology and the opportunities were all sound.
ARCH has worked with exceptional entrepreneurs as well as academic and industry
partners to build more than 160 companies. Among the ARCH-funded companies that
are now public firms or were acquired are Illumina, Aviron, Alnylam
Pharmaceuticals, Kythera Biopharmaceuticals, Receptos, Agios Pharmaceuticals,
Sage Therapeutics, BIND Therapeutics, Fate Therapeutics, Bluebird Bio,
Archaogen, Ikaria, Crystal IS, Nanophase Technologies, deCODE Genetics,
Celebrate Express, Kotura, NeurogesX, Caliper Life Sciences, Classmates.com, XenoPort, New
Era of Networks, Trubion Pharmaceuticals, GenVec, Array BioPharma, Ahura Scientific,
ALIS, MicroOptical Devices, Adolor, Everyday Learning, Innovalight, and R2 Technology.